my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
09-06-2009: BioNTech AG announced the acquisition of all shares of EUFETS AG from Fresenius Biotech GmbH (Munich, Germany). EUFETS, formerly a fully owned subsidiary of Fresenius Biotech GmbH, is a specialist in GMP and GLP services for innovative biopharmaceutical approaches. Under the new owner, EUFETS will retain all facilities, employees and contractual obligations of the former company.
"The investment in EUFETS is an excellent fit endowing BioNTech with synergistic platforms and complementary expertise" commented Prof. Dr. Ugur Sahin, CEO of BioNTech AG, and Dr. Klaus Kühlcke, vice president operations of EUFETS, adding, "We are interested to progress EUFETS into a center of excellence that addresses the needs of individualized medicine by developing and providing a wide range of high-quality GMP/GLP services for innovative approaches such as recombinant vaccines, cell based therapies, gene- and immunotherapies.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab
Swedish Orphan Biovitrum announced a Removab® distribution agreement with Fresenius Biotech. Under the agreement Swedish Orphan Biovitrum (Sobi) will distribute Removab® exclusively in 15 European countries over 7 years. Removab® was granted marketing authorization by the European Commissio ... more
The trifunctional antibody Removab® (Catumaxomab) from Fresenius Biotech was awarded this year’s Galenus von Pergamon Prize in the “Specialist Care” category. The jury acknowledged Removab®’s new therapeutic mechanism and medical relevance for the treatment of malignant ascites. The Galenus ... more
Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation Technology
Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have extended their collaboration in the field of HESylation® Technology. The companies started their cooperation in May 2009 and now have entered into the next phase of development. The extension of the collaboration is combined ... more
Development, manufacturer, sales of gas-measuring devices enviromental and process more
BioNTech AG acquires EUFETS AG
BioNTech AG announced the acquisition of all shares of EUFETS AG from Fresenius Biotech GmbH (Munich, Germany). EUFETS, formerly a fully owned subsidiary of Fresenius Biotech GmbH, is a specialist in GMP and GLP services for innovative biopharmaceutical approaches. Under the new owner, EUF ... more
Jerini AG Reaches Agreement to Sell JPT Peptide Technologies GmbH to TheraCode GmbH
Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
